title: Osteotropic drug delivery system (ODDS) based on bisphosphonic prodrug. I: synthesis and in vivo characterization of osteotropic carboxyfluorescein.
abstract: An osteotropic drug delivery system (ODDS) based on a bisphosphonic prodrug was designed as a novel method for site-specific and controlled delivery of drugs to the bone. Due to the chemical adsorption of bisphosphonic promoiety to the mineral component, hydroxyapatite, a bisphosphonic prodrug is predominantly taken up into the bone. To verify the concept, bisphosphonic promoiety was chemically introduced into 6-carboxyfluorescein (CF) as a model compound and the disposition after intravenous injection was studied in rats. The bisphosphonic prodrug of CF, disodium (fluorescein-6-carbonyloxy) acetoaminomethylene bisphosphonate (CF-BP) was highly taken up to the skeleton (62.1% of dose) and the remainder was excreted into the urine (35.9% of dose). Subsequently, regeneration of CF by hydrolysis of CF-BP in the bone was observed. The microscopic observation showed that CF-BP was buried into the bone with a calcification of the bone. According to the remodeling of the bone, bisphosphonic prodrug buried was supposed to be released in the vicinity of the osteoclast or resorption surface of the bone. Thus, it is suggested that ODDS has a potential to achieve osteoclast-specific or resorption surface-specific targeting of the drugs.
authors.affiliation: Pharmaceutical and Pharmacokinetic Research Laboratories, Fujisawa Pharmaceutical Company Ltd., Osaka, Japan.
authors.forename: J
authors.initials: J
authors.lastname: Fujisaki
authors.forename: Y
authors.initials: Y
authors.lastname: Tokunaga
authors.forename: T
authors.initials: T
authors.lastname: Takahashi
authors.forename: T
authors.initials: T
authors.lastname: Hirose
authors.forename: F
authors.initials: F
authors.lastname: Shimojo
authors.forename: A
authors.initials: A
authors.lastname: Kagayama
authors.forename: T
authors.initials: T
authors.lastname: Hata
mesh_terms: D000818:Animals; D001842:Bone and Bones / Q000166:cytology / Q000378:metabolism*; D002851:Chromatography, High Pressure Liquid; D016503:Drug Delivery Systems; D005269:Femur / Q000033:anatomy & histology / Q000378:metabolism; D005452:Fluoresceins / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D005456:Fluorescent Dyes / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D007275:Injections, Intravenous; D008297:Male; D010010:Osteoclasts / Q000378:metabolism; D011355:Prodrugs / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D005452:Fluoresceins; D005456:Fluorescent Dyes; D011355:Prodrugs; C024098:6-carboxyfluorescein